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Abstract
Purpose—Mind-body therapies (MBT), a subset of complementary and alternative medicine 
(CAM), are used by cancer survivors to manage symptoms related to their cancer experience. 
MBT use may differ by cancer survivorship stage (i.e., acute, short-term, long-term) because each 
stage presents varying intensities of medical activities, associated emotions, and treatment effects. 
We examined the relationship between MBT use and survivorship stage (acute: <1 year; short-
term: 1 to 5 years; long-term: >5 years since diagnosis) using the CAM supplement of the 2012 
National Health Interview Survey. We also examined reported reasons for and outcomes of MBT 
use and frequency of MBT types.
Methods—The sample included cancer survivors (N= 3076) and non-cancer controls (N= 
31,387). Logistic regression tested the relationship of MBT use and survivorship stage. Weighted 
percentages were calculated by survivorship stage for reported reasons and outcomes of use, and 
frequency of MBT types.
Results—MBT use varied by cancer survivorship stage (p = 0.02): acute (8.3%), short-term 
(15.4%), long-term (11.7%) survivorship, and non-cancer controls (13.2%). In the adjusted model, 
short-term survivors had 35% greater odds of MBT use than controls (95% CI: 1.00, 1.83). 
Reasons for and outcomes of MBT use varied among the survivorship stages, with more acute 
survivors reporting medical-related reasons and more short-term survivors reporting to manage 
symptoms.
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Conclusions—MBT may fulfill different symptom management needs at varying stages of 
survivorship. These findings can help inform supportive care services of survivors’ use of MBT for 
symptom burden at each stage and the allocation of these services.
Keywords
Cancer survivors; Cancer Survivorship Stage; Mind Body Therapy; Integrative Health; National 
Health Interview Survey
There are an estimated 14.5 million U.S. cancer survivors, with 64% diagnosed more than 
five years ago [1]. These numbers are projected to increase over the next decade by 22% for 
survivors who will be less than 5 years post-diagnosis and 37% for survivors more than 5 
years post-diagnosis [2]. Importantly, at least 50% of survivors experience lingering physical 
and mental effects of cancer and its treatments (i.e., long-term or late effects) beyond 
treatment completion [3-5]. These effects can include cognitive dysfunction, distress, pain, 
lymphedema, bone density loss, fatigue, sleep problems, reproductive/sexual dysfunction, 
cancer recurrence and new primary cancers, and the development of various chronic diseases 
[6,1,5,4]. This symptom burden can be severe and disruptive to survivor’s quality of life 
(QOL), and, overall, they report worse physical and mental QOL and greater illness burden 
(i.e., health utility, lost productivity, general health status, limitations in activities of daily 
living) than non-cancer controls [7,8].
Cancer survivors may turn to Complementary and Alternative Medicine (CAM) therapies to 
help manage their symptoms [9] and to provide a sense of control over their health [10]. 
Mind-body therapies (MBT) are a subtype of CAM therapies that focus on an interaction 
between the mind (thoughts and emotions), body, and behavior, and are used to alleviate 
physical and/or psychological symptoms, or to increase general wellbeing [11]. Examples 
include yoga, Tai Chi, Pilates, meditation, and guided imagery. Cancer survivors report 
using MBT to manage the effects of cancer and/or treatment including pain [12], stress 
[13-16], anxiety [17,15], depression [17,15], and fatigue [18-20,16]. Moreover, substantial 
evidence supports their efficacy for enhancing coping ability [17] and QOL [13,14,20]. 
MBT are generally accepted by medical professionals, as safe and efficacious non-
pharmacological adjuncts to conventional cancer treatment for symptom management, with 
more cancer hospitals offering them as part of supportive care services [21].
It is possible that MBT use varies by whether one is managing the distress of a recent cancer 
diagnosis and its demanding treatments, transitioning into life after treatment with persisting 
symptoms, or the cancer experience is now a distal past event with few or no lingering 
symptoms [22,23]. As first acknowledged by Mullan’s classic “Seasons of Survival” 
[24,25] , survivorship stages (i.e., acute, transitional, and long-term survivorship) are 
characterized by varying intensities of medical activities, associated emotions, and treatment 
effects (long-term or late effects) [7,26,6,25,24]. As such, these stages may be associated 
with differing use of MBT to fulfill emotional or symptom management needs that 
characterize each survivorship stage.
For instance, the acute survivorship stage, which occurs during the initial cancer diagnosis 
and treatment, is characterized by intense fear and anxiety, and taxing cancer treatments 
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[24,25]. While this period is emotionally charged, it can also serve as an impetus for 
engaging in self-care activities, such as MBT, to cope with extreme distress and for survivors 
to feel some control over their health [27,10]. However, although they may desire to engage 
in such activities, it can also be difficult to do so while in the midst of a busy treatment 
schedule and/or adverse side effects (fatigue, pain, and nausea). The second stage, short-
term survivorship, occurs during the transition from treatment completion and is 
characterized by watchful waiting for cancer recurrence or receiving maintenance treatment, 
balanced with an attempt to return to life as ‘normal’ [25,22,6,24]. This stage can also be 
highly distressing. First, there is often a loss of security felt under the watchful eye of the 
medical team during treatment and there may be difficulties proceeding with life as ‘normal’ 
due to lingering treatment effects and newly emerging late effects [6,25,22]. Moreover, once 
the shock of a cancer diagnosis and a busy treatment schedule has subsided, the experience 
of having been diagnosed with cancer may become more real to survivors. Not only can this 
lead to increased distress, but they may turn to making meaning of their cancer experience 
and developing causal attributions for why the cancer occurred and what behaviors may help 
prevent recurrence [26,28]. Therefore, they may be more likely to engage in self-care 
activities, such as MBT, to reduce distress, manage symptoms, improve health for preventing 
a recurrence, and to feel more in control over their health [10]. Finally, long-term 
survivorship, is characterized by a more complete resumption of normal life activities 
[25,24]. Continual monitoring for cancer recurrence occurs to a lesser extent and 
psychological and physical effects may have diminished [24,25,6,3,29]. As the cancer 
experience becomes a more distal past event, long-term survivors may be less likely to 
engage in MBT considering that survivors’ physical activity levels decrease between 5 and 
10 years post-diagnosis [30] or they may be less likely to use MBT for cancer-related 
reasons if there are fewer persisting symptoms.
However, it is not known whether cancer survivors’ MBT use varies among these 
survivorship stages. Prior studies have examined MBT use either in a single survivorship 
stage or cancer survivors in general (use not reported by survivorship stage). Those studies 
reported MBT use of 64% among survivors within 2 months post-diagnosis [31], 52% 
among survivors 10 to 24 months post-diagnosis [32], 27% among survivors more than 5 
years post-diagnosis [33], and 22% in a general sample of cancer survivors (i.e., not 
examined by survivorship stage) [9]. However, these proportions may be higher than actual 
MBT use because religious activities (prayer) and psychosocial support services were 
included, which are considered more of conventional or standard of care practices rather 
than CAM modalities [34]. Therefore, the prevalence of MBT use among survivorship 
stages is not clear [32,9,34,33].
In this study, we assessed MBT use as defined by the National Center Complementary and 
Integrative Health (NCCIH) [34] - procedures or techniques administered or taught by 
trained practitioners that consisted of relaxation skills or movement-based therapies. Our 
primary aim was to examine the relationship between cancer survivorship stage (i.e., acute 
survivorship: <1 year post-diagnosis; short-term survivorship: 1 to 5 years post-diagnosis; 
long-term survivorship: ≥ 5 years post-diagnosis) and the reported use of MBT in a 
nationally representative sample of adults using the CAM supplement of the 2012 National 
Health Interview Survey (NHIS). A secondary aim was to examine cancer survivors’ 
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reported reasons for and outcomes of their top used MBT, and frequency of use for different 
types of MBT. Understanding how MBT use differs among survivorship stages can inform 
oncology supportive care services of MBT allocation and survivors’ MBT use to manage 
symptom burden at each stage.
METHODS
Participants
This study was based on the Adult CAM Supplement and Sample Adult, Family, and Person 
Core components of the 2012 NHIS. The NHIS collects demographic and health-related 
information through in-person household interviews from a nationally representative sample 
of the U.S. civilian, non-institutionalized, household population [35]. The National Center 
for Health Statistics (NCHS) conducts the NHIS Core annually; the CAM supplement is 
included every 5 years [36,35]. In 2012, 108,131 individuals completed NHIS interviews 
with a 77.6% household response rate [35]. Our study sample included 34,463 adults (ages 
≥18) who had completed the CAM supplement. This secondary data analysis on de-
identified, publicly available NHIS data was determined to be exempt by the UNC-CH 
Institutional Review Board.
Measures
Our primary dependent variable was the use of MBT in the past 12 months, defined as 
having answered “yes” to using any of the following relaxation techniques or movement 
therapies, indicated by the NCCIH [34]: meditations, guided imagery, progressive 
relaxation, biofeedback, hypnosis, yoga, tai chi, qi gong, Trager, Pilates, Feldenkrais, and 
Alexander technique. Psychological therapy or support groups were not included because 
these conventional practices are not considered CAM [34]. To examine participants’ 
reported reasons for and outcomes of their MBT use, we examined those who indicated 
MBT was their top used CAM therapy to be consistent with NHIS questions that were 
directed towards the participant’s top therapy and to exclude other CAM modalities (e.g., 
natural products).
The primary independent variable was cancer survivorship stage. A cancer survivor was 
defined as a respondent who answered “yes” to the question: “have you ever been told by a 
doctor or other health professional that you had cancer or a malignancy of any kind?” This 
definition coincides with that used in cancer survivorship research to identify a survivor 
from the point of cancer diagnosis to end of life, and does not distinguish whether the person 
has active disease or is in remission [37,38]. Cancer survivors were asked a follow-up 
question regarding their age at diagnosis. As reported in analyses of the 2002 NHIS, when 
asked when their cancer first occurred, some participants appeared to have given the number 
of years since diagnosis rather than their age [39,8]. We used the method described in 
greater detail by Yabroff and colleagues [8] to handle these discrepancies: for each cancer 
type, we compared the age at diagnosis to the delay-adjusted incidence rates provided by the 
Surveillance, Epidemiology and End Results (SEER) Program [40]. If the rate was not 
available for a particular age, the value was categorized as “missing.” To examine the 
relationship of MBT use with cancer survivorship, we grouped the years since diagnosis into 
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three stages of survivorship: 1) acute survivorship: less than 1 year; 2) short-term 
survivorship: 1 to 5 years; and 3) long-term survivorship: 5 or more years [6,2].We viewed 
these stages as consistent with Mullan’s ‘seasons of survivorship’: acute survivorship, 
transitional survivorship, and long-term survivorship stages [24,25,22].
Sociodemographics included age (18-44, 45-64, ≥65), gender, race/ethnicity (Non-Hispanic 
white, Non-Hispanic Black, Hispanic, Other—including Asians and American Indians), 
highest education level attained (no college, some college/Associate degree, and Bachelor 
degree or higher), household income (<200%, 200-399%, ≥ 400% of federal poverty 
threshold), health insurance coverage (yes or no) [36,41] , and cancers grouped into main 
types as used in prior research [9] [breast, prostate, colorectal (colon, rectal), gynecological 
(cervical, ovarian, uterine), melanoma (excluding non-melanoma), and other cancers]. The 
NHIS imputes missing values for race/ethnicity and oversamples Non-Hispanic Blacks and 
Hispanics of any race [42]. We evaluated household income in relation to the 2011 poverty 
threshold using five NHIS-generated, multiply imputed datasets [42]. Health insurance 
coverage status consisted of health insurance in some capacity, including Indian Health 
Insurance.
Statistical Analysis
We identified the sociodemographic characteristics of acute, short-term, and long-term 
cancer survivors and those without a history of cancer in our sample by generating sub-
population estimates using the corresponding sample adult weights provided by the NHIS. 
These weights take into account the multi-stage sampling, clustering, and stratification 
design of the NHIS [42]. We calculated the relative standard error of the weighted 
percentages to ensure stability of estimates with a relative standard error of less than 30% 
used as the standard of reliability and precision [36].
We examined the bivariate relationships between the sociodemographic and health 
characteristics and use of MBT in the past 12 months using Pearson’s Chi-square tests. We 
used logistic regression to examine the relationship of MBT use (dependent variable) and 
cancer survivorship stage (independent variable: <1 year since diagnosis, 1 to 5 years since 
diagnosis, ≥5 years since diagnosis). We started with a fully-adjusted model then used a 
change-in-estimate approach to create a more parsimonious adjusted model using a criterion 
of a 10% change in the odds ratio. We calculated weighted percentages for both reasons for 
and outcomes of MBT use (among those who reported MBT as their top therapy) and 
frequency of MBT types, and used Pearson’s Chi-square tests to compare by survivorship 
stages. STATA (v13, StataCorp LP, College Station, TX) was used for all statistical analyses, 
which includes a program for analysis of multiply imputed datasets. All statistical tests were 
two-sided with alpha set at 0.05.
RESULTS
Characteristics of Respondents
The sample included 3076 cancer survivors (acute n = 552, short-term n =825, long-term n = 
1699 survivorship stages) and 31,387 non-cancer controls. Overall, cancer survivors tended 
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to be older, Non-Hispanic White, and have health insurance compared with non-cancer 
controls (Table 1). Long-term cancer survivors were more likely to be older, female, and 
have a breast or gynecological cancer diagnosis than acute and short-term cancer survivors 
(Table 1).
MBT Use in the Past 12 Months
Overall MBT use in the past 12 months was 13.1% (Table 2). MBT use varied by cancer 
survivorship stage, with short-term cancer survivors reporting the greatest use (15.4%), 
followed by non-cancer controls (13.2%), long-term survivors (11.7%), and acute survivors 
(8.3%; p < 0.02). All sociodemographic characteristics were significantly related to MBT 
use (Table 2). Women, respondents younger than 65 years old, Non-Hispanic White or Other 
race, and individuals with health insurance were more likely to report MBT use.
In the logistic regression model adjusted for gender, age, race/ethnicity, and income, more 
short-term cancer survivors reported MBT use in the past 12 months than those with no 
history of cancer (OR=1.35, 95% CI: 1.00, 1.82), whereas acute and long-term survivorship 
stages did not significantly different from controls (Table 3).
Reasons for and Outcomes of MBT Use and frequency of MBT Types
Among respondents who reported MBT as their top CAM therapy (N = 2242), more acute 
survivors reported using MBT to treat a medical condition (46% vs. 30% short-term, 33% 
long-term, and 22% controls, p=.02, Table 4) and to improve immune function (56% vs. 
28% short-term, 33% long-term, and 29% controls, p=.09). Whereas, more short-term 
survivors reported using MBT to improve memory (56% vs. 43% acute, 43% long-term, and 
35% controls, p<.047). Although the most frequently reported reason for MBT use across 
survivorship stages was for general wellness and disease prevention, this did not 
significantly differ among stages (80% acute, 88% short-term, 70% long-term, p=.19).
For outcomes of MBT use, more acute survivors reported that use of MBT helped them to 
cope better with health problems (80% vs. 57% short-term, 56% long-term, and 43% 
controls, p<.0001, Table 4) and improve sleep (82% vs. 53% short-term, 52% long-term, and 
62% controls, p=.08). The most frequently reported MBT outcome across survivorship 
stages, which did not differ among stages, was that it reduced stress or contributed to 
relaxation (86% acute, 88% short-term, 85% long-term, p=.97).
Next, we examined the use of different MBT types in the past 12 months (Table 5). More 
short-term survivors (9.9%) and controls (9.4%) reported using yoga than acute (4.3%) and 
long-term survivors (7.4%, p=.005). Additionally, more short-term survivors (3.1%) and 
controls (2.1%) reported use of Pilates than acute (1.6%) and long-term survivors (1.2%, p=.
05). Finally, reported use of guided imagery was greater across the three survivorship stages 
(acute 3.0%, short-term 2.3%, long-term 2.6%) than reported by controls (1.6%, p=.03).
DISCUSSION
Mullan’s classic “Seasons of Survival” [24,25] first acknowledged that ‘seasons’ or stages of 
survivorship are characterized by varying intensities of medical activities, associated 
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emotions, and management of new or lingering treatment effects [7,26,6,25,24]. Cancer 
survivors report using CAM therapies, including MBT, to help manage symptom burden 
[9,39]. However, prior studies have not examined MBT use by survivorship stages (e.g., one 
stage or across stages was examined) [33,32,31] or have included conventional approaches 
(religious activities and/or psychological support services) in their overall assessment of 
MBT use [9,32,39]. Therefore, overall MBT use among cancer survivorship stages was 
unclear. Using the large population-based sample of the 2012 NHIS CAM supplement, we 
examined whether MBT use and reported reasons for and outcomes of this use differed 
among survivorship stages.
Overall, we found that more short-term cancer survivors reported MBT use, followed by 
non-cancer controls, long-term survivors, and then acute survivors reporting the least 
amount of use. Furthermore, short-term survivors had 35% greater odds of MBT use than 
non-cancer controls. Several factors may account for why more short-term survivors 
reported MBT use than acute and long-term survivors. The short-term survivorship stage is a 
transitional stage that bridges treatment completion with the return to life as ‘usual’. 
However, although intense treatment regimens may be completed (i.e., exception of 
maintenance therapies), the desire to move on with life is often juxtaposed by cancer-related 
distress (e.g., fear of recurrence, anxiety) and lingering or new physical symptoms [6,25,22]. 
Likewise, short-term survivors’ most frequently reported reasons of MBT use were for 
general wellness or disease prevention and, in comparison to acute and long-term, they were 
more likely to report using MBT to improve memory. Additionally, their most frequently 
reported outcomes of MBT use were that it reduced stress and improved overall health or 
felt better. Finally, their most frequently reported MBT types consisted of relaxation-based 
activities (i.e., meditations, progressive relaxation), although similar to the other stages, but 
they also reported using more movement-based MBT types (yoga, Pilates) than the other 
survivorship stages. Consistent with the challenges characterizing this transitional period, 
this suggests that MBT may be fulfilling needs to address distress (e.g., fear of cancer 
recurrence[43]), desires to improve health (i.e., engagement in more physically active 
MBTs, such as Pilates and yoga), and to manage treatment-related effects (i.e., cognitive 
impairments [44]).
On the other hand, although fewer acute cancer survivors reported MBT use, they reported 
more medical-based reasons for their use (i.e., to treat medical condition, improve immune 
function) and MBT outcomes relevant to undergoing treatment (i.e., it helped to sleep better, 
cope better with health problems) than short-term and long-term survivors. It also appeared 
they reported more MBT types consistent with coping during treatment (i.e., meditation, 
progressive relaxation, guided imagery). During the acute stage, survivors may feel too 
overwhelmed with treatment demands (i.e., time, fatigue, pain, nausea) to utilize MBT, but 
recognize their potential benefits for coping with treatment demands.
Finally, we found that the long-term survivors reported MBT use that was generally between 
acute and short-term survivors’ reported use. In this stage, their most frequently reported 
MBT reason was for general wellness/disease prevention (although, to a lesser extent than 
the other survivorship stages). The most frequently reported outcomes of MBT use were 
reduced stress, overall health improvement, and they felt better emotionally. This seems to 
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point to more general reasons and outcomes of MBT use, rather than reasons or outcomes 
indicating medical (i.e., immune function) or symptom specific needs (i.e., improve 
memory). Their reported MBT use consisted mainly of yoga (although, to a lesser extent 
than short-term survivors), fewer reports of some relaxation-based activities (i.e., 
meditations), and use of guided imagery and progressive relaxation comparable to the other 
stages. Overall, this suggests that long-term survivors’ may have been using MBT less to 
manage needs associated with undergoing treatment or cancer-related symptoms. Instead, 
were using MBT for general health and wellbeing needs, consistent with research that long-
term survivors experience improvements in the cancer burden [45].
These findings should be interpreted within the context of a few limitations. First, the NHIS 
relies on self-reported measures that are not confirmed by medical chart review, which may 
have led to under-reporting of cancer diagnoses and incorrect age at diagnosis. Second, our 
findings for survivors’ reported reasons for and outcomes of MBT and MBT types are 
limited to the small number of survivors who reported MBT as their top CAM therapy or 
responded to that portion of the survey. Third, we were unable to determine proportion of 
survivors in each stage who had an established MBT practice prior to cancer diagnosis as 
they may have been more likely to continue this practice throughout survivorship. Finally, 
the NHIS is limited to individuals residing in households and who are well enough to 
participate.
CONCLUSION
In summary, these results indicate that cancer survivors’ use of MBT and their reported 
reasons and outcomes vary by cancer survivorship stage, indicating MBT fulfills different 
needs associated with each stage. Future research should determine barriers and facilitators 
of MBT use among these survivorship stages, particularly regarding acute survivors’ less use 
of MBT. It may be that as more cancer hospitals implement MBT as part of their oncology 
supportive services, survivors in the acute survivorship stage are more likely to use and 
benefit from these. Understanding how the use of MBT differs among survivorship stages 
can be used to inform the allocation of these services in oncology supportive care as 
noninvasive therapies to help survivors manage their cancer symptom burden.
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Table 1
Sociodemographic and Health Characteristics of Study Population by Cancer Survivorship Stage
No History of
Cancer Acute Survivorship
Short-term
Survivorship
Long-term
Survivorship
N % N % N % N %
Total 31,387 91.5 552 1.55 825 2.39 1,699 4.53
Gender
 Female 17,350 51.4 297 49.9 472 55.2 1086 59.9
Age (years)
 18-44 14,960 50.6 65 10.9 99 14.2 156 9.9
 45-64 10,742 34.6 196 42.9 323 40.9 567 35.0
 ≥ 65 5,686 14.7 291 46.2 403 44.9 976 55.0
Ethnicity and Race
 Non-Hispanic White 18,297 65.4 454 86.9 669 85.3 1377 85.8
 Hispanic, Any race 5,672 15.8 29 3.19 52 5.2 98 5.1
 Non-Hispanic Black 4,984 12.4 55 6.71 73 5.6 163 6.1
 Other 2,434 6.4 14 3.16 31 3.9 61 3.2
Highest Education Level
Attained
 No college 13,140 40.5 248 44.1 309 32.9 702 40.3
 Some college/Associate
 degree 9,633 31.4 156 29.5 265 34.6 509 31.3
 Bachelor degree or
 higher 8,477 28.2 144 26.4 249 32.4 484 28.3
Household Income in
relation to 2011 Federal
Poverty Threshold1
 <200% 73,482 43.1 1098 34.9 1,470 31.1 3,336 34.0
 200% - 399% 52,218 48.0 978 31.0 1,362 28.8 3,132 32.0
 ≥400% 56,094 30.8 1074 34.1 1,890 40.0 3,294 33.0
Health Insurance in some
capacity, including IHS
 Yes 25,374 82.1 525 95.6 769 93.9 1,590 94.3
Cancer Types
 Breast -- -- 92 14.0 146 15.1 324 17.9
 Prostate -- -- 58 11.6 116 14.4 187 11.5
 Colorectal -- -- 34 5.21 69 6.80 96 4.90
 Gynecological -- -- 42 5.60 69 7.62 296 15.4
 Melanoma -- -- 65 12.6 64 8.34 114 7.76
 Other Cancers -- -- 185 36.3 249 34.2 429 27.6
Note. Data source: NHIS, 2012. Estimates are based on household interviews of a sample of the civilian, noninstitutionalized population. 
Percentages are age adjusted using the projected 2010 U.S. population as the standard population. Acute survivorship: <1 year post-diagnosis, 
short-term survivorship: 1 to 5 years post-diagnosis, long-term survivorship: ≥ 5 years post-diagnosis.
1
Household income was generated from five imputed datasets to account for missing values, income N is based on the five imputed dataset.
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Table 2
Bivariate Relationships Between Use of Mind-Body Therapies1in Past 12 Months and Sociodemographic and 
Health Characteristics Among US Adults
N % 95% CI
Overall Use 4310 13.1 12.6, 13.7
Cancer Survivorship Status
 No history of cancer 3940 13.2 12.6, 13.8
 Acute Survivorship 46 8.3 5.7, 11.9
 Short-term Survivorship 107 15.4 12.1, 19.5
 Long-term Survivorship 212 11.7 10.0, 13.7
Gender
 Male 1245 8.4 7.8, 9.1
 Female 3065 17.5 16.7, 18.3
Age (years)
 18-44 2400 15.8 15.0, 16.7
 45-64 1436 12.7 11.9, 13.5
 ≥ 65 474 6.7 5.9, 7.5
Ethnicity and Race
 Non-Hispanic White 3056 14.9 14.2, 15.6
 Non-Hispanic Black 423 8.4 7.4, 9.5
 Hispanic, Any race 425 7.3 6.5, 8.23
 Other 406 16.5 14.5, 18.6
Highest education level attained
 No college 659 5.23 4.7, 5.8
 Some college/Associate degree 1477 14.0 13.1, 14.9
 Bachelor degree or higher 2169 23.4 22.1, 24.5
Household Income in relation to 2011
Federal Poverty Threshold 2
 <200% 7356 33.4 32.6, 34.2
 200% - 399% 6768 29.7 29.1, 30.4
 ≥400% 11,622 36.8 35.9, 37.7
Health Insurance in some capacity,
including IHS
 Yes 3707 13.7 13.1, 14.3
Note. Data source: NHIS, 2012. Estimates are based on household interviews of a sample of the civilian, noninstitutionalized population. 
Percentages are age adjusted using the projected 2010 U.S. Acute survivorship: <1 year post-diagnosis, short-term survivorship: 1 to 5 years post-
diagnosis, long-term survivorship: ≥ 5 years post-diagnosis.
1
Mind-body therapies includes biofeedback, hypnosis, yoga, tai chi, qi gong, Trager, Pilates, Feldenkrais, Alexander technique, mindfulness 
meditation, mantra meditation, spiritual meditation, guided imagery, and progressive relaxation.
2
Household income was generated from five imputed datasets to account for missing values. The income N is based on these five imputed datasets.
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Table 3
Use of Mind-Body Therapies in Past 12 Months Among US Adults by Cancer Survivorship Stage
Unadjusted Model Adjusted Model
OR 95% CI OR 95% CI
 No History of cancer
(referent) 1.00 1.00
 Acute survivorship 0.70 0.45, 1.09 0.73 0.48, 1.11
 Short-term survivorship 1.27 0.92, 1.75 1.35 1.00, 1.82
Long-term survivorship 0.98 0.78, 1.24 1.08 0.90, 1.31
Note. Data source: NHIS, 2012. Estimates are based on household interviews of a sample of the civilian, noninstitutionalized population. Odds 
ratios are age adjusted using the projected 2010 U.S. population as the standard population. Acute survivorship: <1 year post-diagnosis, short-term 
survivorship: 1 to 5 years post-diagnosis, long-term survivorship: ≥ 5 years post-diagnosis. Final model is adjusted for race/ethnicity, gender, 
income, and age.
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Table 4
Reasons and Outcomes for Mind-Body Therapy Use Reported as Top Therapy
No History of
Cancer
Acute
Survivorship
Short-term
Survivorship
Long-term
Survivorship
N % N % N % N % p-value
Total Sample of MBT Users1 2062 92.8 28 1.1 48 2.3 104 3.8
Reasons for MBT Use:
 For general wellness/or disease prevention 1569 76 21 80 40 88 72 70 .19
 To improve energy 1342 64.6 21 61.3 25 48.4 55 55.7 .17
 For immune function 631 29 15 56 15 28 36 33 .09
 To improve memory 749 35 13 43.3 22 56.2 42 43 .047
 To treat a medical condition 452 22.3 10 46.3 17 29.8 37 33.1 .02
MBT led to these outcomes:
 Gave sense of control over one’s health 1231 60 17 64 28 49 57 52 .37
 Reduced stress or for relaxation 1771 87 24 86 41 88 92 85 .97
 Slept better 842 62 15 82.1 23 53.4 43 52.2 .08
 Felt emotionally better 1512 74 22 82.9 34 66.2 77 70.6 .54
 Coped better with health problems 920 42.9 20 80.5 26 57.4 57 55.9 .0001
 Improved overall health, felt better 1665 81 21 81 39 77.4 76 71.5 .31
Note. Acute survivorship: <1 year post-diagnosis, short-term survivorship: 1 to 5 years post-diagnosis, long-term survivorship: ≥ 5 years post-
diagnosis.
1
The sample for this table includes data for survey respondents who stated that MBT was their top therapy and they reported on reasons for MBT 
use and its outcomes. Additionally, respondents could answer more than one reason for MBT use and outcome. p-values are based on two-sided 
Chi-square analyses.
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Table 5
Types of Mind-Body Therapies in Past 12 Among US Adults by Cancer Survivorship Status
No History of
Cancer
Acute
Survivorship
Short-term
Survivorship
Long-term
Survivorship
N % N % N % N % p-value
Overall use 3940 13.2 46 8.2 107 15.4 212 11.7 .02
Mindfulness meditation 579 1.9 12 2.4 17 2.6 36 1.8 .66
Mantra meditation 502 1.6 12 2.5 22 2.7 31 1.4 .13
Spiritual meditation 924 3.0 21 3.6 30 4.5 65 3.3 .32
Progressive relaxation 650 2.0 16 3.2 26 2.9 47 2.7 .14
Guided imagery 496 1.6 13 3.0 21 2.3 47 2.6 .03
Biofeedback 95 0.3 2 0.2 4 0.7 6 0.3 .30
Hypnosis 81 0.26 0 0.0 2 0.4 7 0.36 .68
Yoga 2,753 9.4 25 4.3 71 9.9 122 7.4 .005
Tai Chi 378 1.1 10 1.6 13 1.9 29 1.2 .21
Qigong 134 0.35 2 0.2 3 0.25 11 0.5 .51
Trager 10 0.03 1 0.02 1 0.03 0 0 .71
Pilates 593 2.1 8 1.6 23 3.1 24 1.2 .05
Feldenkrais 15 0.04 2 0.5 2 0.03 1 0.01 <.001
Alexander Technique 29 0.1 1 0.3 1 0.02 0 0 .31
Note. Acute survivorship: <1 year post-diagnosis, short-term survivorship: 1 to 5 years post-diagnosis, long-term survivorship: ≥ 5 years post-
diagnosis. The sample for this table includes data for individuals who reported MBT use in past 12 months and responded to items. p-values are 
based on two-sided Chi-square analyses.
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